Pediatric Pheochromocytoma Medication
- Author: Patricia Myriam Vuguin, MD, MSc; Chief Editor: Max J Coppes, MD, PhD, MBA more...
Medication Summary
Although surgical removal is the definitive treatment of pheochromocytoma, pharmacologic therapy plays a critical role in control of blood pressure, both perioperatively and long-term in patients with inoperable disease. Alpha-adrenergic antagonists and beta-adrenergic antagonists, often in combination, as well as nitrates are used for this purpose. Antiarrhythmic agents are used to control the ventricular tachyarrhythmias that these patients may experience.
Alpha-Adrenergic Blocking Agents
Class Summary
These agents are used preoperatively in combination with beta-blockers. At low doses, alpha-adrenergic receptor blockers may be used as monotherapy in the treatment of hypertension. At higher doses, the agents may cause sodium and fluid to accumulate. As a result, concurrent diuretic therapy may be required to maintain the hypotensive effects of the alpha-receptor blockers.
Phenoxybenzamine (Dibenzyline)
This alpha1- and alpha2-adrenergic blocking agent blocks circulating epinephrine and norepinephrine action, reducing hypertension. It decreases sympathetic tone on the vasculature, dilates blood vessels, and lowers arterial blood pressure. Long-acting properties produce and maintain a chemical sympathectomy. Phenoxybenzamine lowers supine and upright blood pressures. It does not affect the parasympathetic nervous system.
Phentolamine (Oraverse)
Phentolamine is an alpha1- and alpha2-adrenergic blocking agent that blocks circulating epinephrine and norepinephrine action, reducing hypertension that results from catecholamine effects on the alpha-receptors. Drug action is transient and alpha-adrenergic blockade is incomplete. This agent is often used immediately prior to or during adrenalectomy to prevent or control paroxysmal hypertension that results from anesthesia, stress, or operative manipulation of the tumor. It is a first-line agent to treat hypertensive crisis.
Prazosin (Minipress)
Prazosin is a postsynaptic alpha1-antagonist. It decreases blood pressure with minimal risk of reflex tachycardia.
Beta-Adrenergic Blocking Agents
Class Summary
These agents are used as adjunctive therapy for cardiac effects. The agents inhibit chronotropic, inotropic, and vasodilatory responses to beta-adrenergic stimulation.
Propranolol (Inderal LA, InnoPran XL)
Propranolol is a nonselective beta-adrenergic receptor blocker. After primary treatment with an alpha-receptor blocker, propranolol may be used as adjunctive therapy if control of tachycardia becomes necessary before or during surgery.
This agent may be used to treat excessive beta-receptor stimulation in patients with inoperable metastatic pheochromocytoma. It has membrane-stabilizing activity and decreases automaticity of contractions. It decreases the effects of the sympathetic nervous system on the heart and juxtaglomerular apparatus, release of renin, and blood pressure. It acts in the CNS to reduce sympathetic outflow and vasoconstrictor tone. Propranolol is not suitable for emergency treatment of hypertension; do not administer IV in hypertensive emergencies.
Labetalol (Trandate)
Labetalol blocks beta1-, alpha-, and beta2-adrenergic receptor sites, thus decreasing blood pressure.
Esmolol (Brevibloc)
Esmolol is an excellent drug for use in patients at risk for experiencing complications from beta-blockade, particularly those with reactive airway disease, mild-to-moderate LV dysfunction, and/or peripheral vascular disease. Its short half-life of 8 min allows for titration to desired effect and quick discontinuation if needed.
Nitrates
Class Summary
These agents provide peripheral and coronary vasodilation.
Sodium nitroprusside (Nitropress)
Sodium nitroprusside acts directly on vascular smooth muscle to cause vasodilatation and reduce blood pressure. It also has a positive inotropic effect.
Antiarrhythmic Agents
Class Summary
These agents alter the electrophysiologic mechanisms responsible for arrhythmia.
Amiodarone (Cordarone, Pacerone)
Amiodarone may inhibit atrioventricular (AV) conduction and sinus node function. This agent prolongs action potential and refractory period in myocardium and inhibits adrenergic stimulation. Before administration, control the ventricular rate and CHF (if present) with digoxin or calcium channel blockers.
Lidocaine (Xylocaine)
Lidocaine is a class IB antiarrhythmic that increases electrical stimulation threshold of the ventricle, suppressing automaticity of conduction through the tissue.
Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. May 2010;95(5):2023-37. [Medline].
Eisenhofer G, Huynh TT, Elkahloun A, Morris JC, Bratslavsky G, Linehan WM. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab. Nov 2008;295(5):E1223-33. [Medline].
Tischler AS, Powers JF, Alroy J. Animal models of pheochromocytoma. Histol Histopathol. Jul 2004;19(3):883-95. [Medline].
Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, Solis DC. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis. 2009;26(3):239-50. [Medline].
Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X. Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol. Mar 2009;217(4):597-604. [Medline].
Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. Dec 1 2005;23(34):8812-8. [Medline].
Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B. Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine. Aug-Dec 2008;34(1-3):96-100. [Medline].
Zelinka T, Musil Z, Dušková J, et al. Metastatic pheochromocytoma: Does the size and age matter?. Eur J Clin Invest. Oct 2011;41(10):1121-1128. [Medline]. [Full Text].
Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. Jul 2005;258(1):55-66. [Medline].
Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. Dec 2008;15(4):1127-33. [Medline].
Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. Aug 5 2011;[Medline].
Yu R, Nissen NN, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007. Am J Med. Jan 2009;122(1):85-95. [Medline].
Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. Jul 2011;96(7):2004-15. [Medline].
Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology. Feb 2009;41(2):173-7. [Medline].
Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. Dec 2007;92(12):4602-8. [Medline].
Giovanella L, Ceriani L, Balerna M, Keller F, Taborelli M, Marone C, et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging. Mar 2008;52(1):84-88. [Medline].
Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. Apr 2009;50(4):513-9. [Medline].
Fiebrich HB, Brouwers AH, van Bergeijk L, van den Berg G. Image in endocrinology. Localization of an adrenocorticotropin-producing pheochromocytoma using 18F-dihydroxyphenylalanine positron emission tomography. J Clin Endocrinol Metab. Mar 2009;94(3):748-9. [Medline].
Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. Mar 2009;16(1):255-65. [Medline].
Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. Mar 2008;15(1):311-23. [Medline].
Dannenberg H, van Nederveen FH, Abbou M, et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol. Mar 20 2005;23(9):1894-901. [Medline].
Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma?. Clin Endocrinol (Oxf). Mar 2009;70(3):354-7. [Medline].
Jimenez C, Cote G, Arnold A, Gagel RF. Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?. J Clin Endocrinol Metab. May 30 2006;[Medline]. [Full Text].
Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. May 9 2002;346(19):1459-66. [Medline].
Brouwers FM, Petricoin EF 3rd, Ksinantova L, Breza J, Rajapakse V, Ross S, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer. Jun 2005;12(2):263-72. [Medline].
Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, et al. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann Surg. Dec 2009;250(6):983-90. [Medline].
Brouwers FM, Elkahloun AG, Munson PJ, et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci. Aug 2006;1073:541-56. [Medline].
Gosse P, Tauzin-Fin P, Sesay MB, Sautereau A, Ballanger P. Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose?. J Hum Hypertens. Sep 2009;23(9):605-9. [Medline].
Shonkwiler RJ, Lee JA. Laparoscopic retroperitoneal adrenalectomy. Surg Laparosc Endosc Percutan Tech. Aug 2011;21(4):243-7. [Medline].
[Guideline] International Pediatric Endosurgery Group. IPEG guidelines for the surgical treatment of adrenal masses in children. J Laparoendosc Adv Surg Tech A. Mar 2010;20(2):vii-ix. [Medline].
St Peter SD, Valusek PA, Hill S, et al. Laparoscopic adrenalectomy in children: a multicenter experience. J Laparoendosc Adv Surg Tech A. Sep 2011;21(7):647-9. [Medline].
Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. Oct 15 2008;113(8):2020-8. [Medline].
Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. Jan 2009;94(1):5-9. [Medline].
Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. May 2009;39(5):327-31. [Medline].
Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. Feb 2009;94(2):386-91. [Medline].
Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol. 2004;5:315-25. [Medline].
Print
